Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart.

Activation of cardiac STAT3 by IL-6 cytokine family contributes to cardioprotection. Previously, we demonstrated that IL-11, an IL-6 cytokine family, has the therapeutic potential to prevent adverse cardiac remodeling after myocardial infarction; however, it remains to be elucidated whether IL-11 exhibits postconditioning effects. To address the possibility that IL-11 treatment improves clinical outcome of recanalization therapy against acute myocardial infarction, we examined its postconditioning effects on ischemia/reperfusion (I/R) injury. C57BL/6 mice were exposed to ischemia (30 min) and reperfusion (24 h), and IL-11 was intravenously administered at the start of reperfusion. I/R injury mediated the activation of STAT3, which was enhanced by IL-11 administration. IL-11 treatment reduced I/R injury, analyzed by triphenyl tetrazolium chloride staining [PBS, 46.7 ± 14.4%; IL-11 (20 μg/kg), 28.6 ± 7.5% in the ratio of infarct to risk area]. Moreover, echocardiographic and hemodynamic analyses clarified that IL-11 treatment preserved cardiac function after I/R. Terminal deoxynucleotide transferase-mediated dUTP nick-end labeling staining revealed that IL-11 reduced the frequency of apoptotic cardiomyocytes after I/R. Interestingly, IL-11 reduced superoxide production assessed by in situ dihydroethidium fluorescence analysis, accompanied by the increased expression of metallothionein 1 and 2, reactive oxygen species (ROS) scavengers. Importantly, with the use of cardiac-specific STAT3 conditional knockout (STAT3 CKO) mice, it was revealed that cardiac-specific ablation of STAT3 abrogated IL-11-mediated attenuation of I/R injury. Finally, IL-11 failed to suppress the ROS production after I/R in STAT3 CKO mice. IL-11 administration exhibits the postconditioning effects through cardiac STAT3 activation, suggesting that IL-11 has the clinical therapeutic potential to prevent I/R injury in heart.

[1]  G. Heusch,et al.  Cardioprotection by Ischemic Postconditioning Is Lost in Aged and STAT3-Deficient Mice , 2008, Circulation research.

[2]  I. Kawase,et al.  Cardiac-specific Activation of Signal Transducer and Activator of Transcription 3 Promotes Vascular Formation in the Heart* , 2002, The Journal of Biological Chemistry.

[3]  I. Kawase,et al.  Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine. , 2007, Cytokine.

[4]  Hiroshi Yamamoto,et al.  Leukemia Inhibitory Factor Induces Endothelial Differentiation in Cardiac Stem Cells* , 2006, Journal of Biological Chemistry.

[5]  C. Nienaber,et al.  Preservation From Left Ventricular Remodeling by Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Use of Granulocyte-Colony–Stimulating Factor (FIRSTLINE-AMI) , 2005, Circulation.

[6]  D. Hilfiker-Kleiner,et al.  Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis , 2007, Basic Research in Cardiology.

[7]  G. Heusch,et al.  Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion , 2010, Basic Research in Cardiology.

[8]  D. Williams,et al.  Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis. , 1997, The American journal of physiology.

[9]  R. Bolli,et al.  Mechanism of cyclooxygenase-2 upregulation in late preconditioning. , 2003, Journal of molecular and cellular cardiology.

[10]  Sheryl E. Koch,et al.  Regulating RISK: a role for JAK-STAT signaling in postconditioning? , 2008, American journal of physiology. Heart and circulatory physiology.

[11]  P. Doevendans,et al.  Targeted Inhibition of p38 Mitogen-activated Protein Kinase Antagonizes Cardiac Injury and Cell Death Following Ischemia-Reperfusion in Vivo* , 2004, Journal of Biological Chemistry.

[12]  I. Komuro,et al.  G-CSF therapy for acute myocardial infarction. , 2007, Trends in pharmacological sciences.

[13]  I. Kawase,et al.  STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. , 2005, Cardiovascular research.

[14]  D. Hilfiker-Kleiner,et al.  STAT3 and cardiac remodeling , 2010, Heart Failure Reviews.

[15]  M. Schwaiger,et al.  Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. , 2006, JAMA.

[16]  Y. Fujio,et al.  Activation of Signal Transducer and Activator of Transcription 3 Protects Cardiomyocytes from Hypoxia/Reoxygenation-Induced Oxidative Stress Through the Upregulation of Manganese Superoxide Dismutase , 2001, Circulation.

[17]  I. Komuro,et al.  Therapeutic Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-11 Ameliorates Cardiac Fibrosis After Myocardial Infarction , 2010, Circulation.

[18]  I. Komuro,et al.  Granulocyte Colony Stimulating Factor Directly Inhibits Myocardial Ischemia-Reperfusion Injury Through Akt–Endothelial NO Synthase Pathway , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[19]  P. Patterson,et al.  Leukemia Inhibitory Factor, Interleukin 6, and Other Cytokines Using the GP130 Transducing Receptor: Roles in Inflammation and Injury , 1999, Stem cells.

[20]  I. Komuro,et al.  Leukemia Inhibitory Factor Enhances Survival of Cardiomyocytes and Induces Regeneration of Myocardium After Myocardial Infarction , 2003, Circulation.

[21]  D. Williams,et al.  Interleukin-11: review of molecular, cell biology, and clinical use. , 1997, Blood.

[22]  D. Hilfiker-Kleiner,et al.  Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis , 2007, Basic Research in Cardiology.

[23]  Michael D. Schneider,et al.  Signal Transducer and Activator of Transcription 3 Is Required for Myocardial Capillary Growth, Control of Interstitial Matrix Deposition, and Heart Protection From Ischemic Injury , 2004, Circulation research.

[24]  L. Opie,et al.  Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. , 2009, Cardiovascular research.

[25]  B. Sands,et al.  Randomized, controlled trial of recombinant human interleukin‐11 in patients with active Crohn's disease , 2002, Alimentary pharmacology & therapeutics.

[26]  S. S. Zhang,et al.  Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  I. Komuro,et al.  G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes , 2005, Nature Medicine.

[28]  Y. Fujio,et al.  Signal Transducer and Activator of Transcription 3 Is Required for Glycoprotein 130-mediated Induction of Vascular Endothelial Growth Factor in Cardiac Myocytes* , 2000, The Journal of Biological Chemistry.

[29]  D. Geschwind,et al.  Disruption of Astrocyte STAT3 Signaling Decreases Mitochondrial Function and Increases Oxidative Stress In Vitro , 2010, PloS one.

[30]  W. McCaskill-Stevens,et al.  A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. , 1996, Blood.